WeVote
Log In

Bill

Bill

S 875

An Act to promote transparency in prescription drug prices

194th Legislature (2025-2026) Introduced by Ed Kennedy

Massachusetts requires pharmaceutical companies to publicly disclose drug pricing data to increase market transparency and help consumers and regulators understand medication costs.

Accompanied S868
0
WeVote Research Nonpartisan
Bill Summary · S 875

Legislative bill overview

S 875 seeks to increase transparency in prescription drug pricing by requiring pharmaceutical companies and intermediaries to disclose pricing information to the public and state regulators. The bill aims to make drug cost data more accessible so consumers and policymakers can better understand what drives medication prices in Massachusetts.

Why is this important

Prescription drug costs are a major healthcare expense for Massachusetts residents, and lack of price transparency makes it difficult for consumers to shop for medications or advocate for lower costs. Greater transparency could help identify pricing disparities, inform policy decisions, and potentially reduce overall drug spending through increased market competition and public awareness.

Potential points of contention

  • Industry opposition: Pharmaceutical manufacturers may argue that disclosing pricing information reveals proprietary business strategies and reduces competitive advantage, potentially impacting innovation incentives.
  • Implementation complexity: Defining what pricing data must be disclosed (list prices vs. negotiated rates), to whom, and in what format could create regulatory burdens and disagreements over feasibility.
  • Federal preemption concerns: The pharmaceutical industry may challenge whether individual states can impose pricing transparency requirements without conflicting with federal drug pricing authority and interstate commerce regulations.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.